STOCK TITAN

Evogene names Dr. Adi Zuluf-Shani as board chair

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) announced management changes. Its Board appointed Dr. Adi Zuluf-Shani as Chairperson, effective November 18, 2026. VP Finance Polina Ravzin notified the company of her resignation, effective November 22, 2026; Evogene said it was for personal reasons and not due to disagreement over the company’s operations, policies or practices. Rephael Haim was appointed VP Finance effective November 22, 2026.

Before joining Evogene, Haim served as Head of Financial Planning and Analysis at Nanox Imaging and as VP Finance and head of FP&A at Questar Auto Technologies. He also served as an Evogene controller from 2019 to 2022.

Chairperson appointment effective date November 18, 2026 Dr. Adi Zuluf-Shani’s appointment as Chairperson of the Board
VP Finance transition effective date November 22, 2026 Polina Ravzin’s resignation and Rephael Haim’s appointment as VP Finance
FP&A financial
"VP Finance and head of FP&A at Questar Auto Technologies"
Financial planning and analysis (FP&A) involves examining a company's financial data to help guide its future decisions. It’s like creating a detailed roadmap that shows where the business is now, where it wants to go, and how to get there. Investors rely on FP&A to understand a company's financial health and its potential for growth, making it a key tool for assessing investment opportunities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new chairperson of EVGN?

Dr. Adi Zuluf-Shani was appointed Chairperson of Evogene’s Board, effective November 18, 2026.

Who is EVGN’s new VP Finance?

Rephael Haim was appointed VP Finance effective November 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-36187

 

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

 

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

CONTENTS

 

Changes in Management

 

Evogene Ltd., or the Company, reports changes in its management.

 

Evogene Ltd’s Board of Directors (“Board”) has appointed Dr. Adi Zuluf-Shani as Chairperson of the Board, as of November 18 2026.

 

In addition, Ms. Polina Ravzin, the Company’s VP Finance, notified her resignation from her position effective as of November 22, 2026. The resignation of Ms. Ravsin was due to personal reasons and was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

 

The Company has appointed Mr. Rephael Haim as its new VP Finance, affective from November 22 2026. Prior to joining the Company, Mr. Haim served as Head of Financial planning and analysis at Nanox Imaging (NASDAQ: NNOX), and as VP Finance and head of FP&A at Questar Auto Technologies. During 2019-2022 Mr. Haim was also a controller at Evogene Ltd..

 

Evogene wishes Dr. Zuluf Shani and Mr. Haim success with their new positions in the Company. Evogene expresses its gratitude to Ms. Polina Ravsin for her contributions during her tenure.

 

This Form 6-K is incorporated by reference into the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 




Date: November 19, 2026
EVOGENE LTD.
(Registrant)

By: /s/ Ofer Haviv
Ofer Haviv
President and Chief Executive Officer

 

 

Keep reading